AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$60.50
pos +0.00
+0.00%
Today's Range: 60.37 - 60.99 | ABBV Avg Daily Volume: 9,597,000
Last Update: 02/27/15 - 4:00 PM EST
Volume: 0
YTD Performance: -7.55%
Open: $0.00
Previous Close: $60.52
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,886,909
Market Cap: 96,462,035,733
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 8 6
Moderate Buy 0 0 0 1
Hold 4 4 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.73 1.55 1.65
Latest Dividend: 0.51
Latest Dividend Yield: 3.37%
Dividend Ex-Date: 04/13/15
Price Earnings Ratio: 55.02
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
55.02 54.90 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-11.94% 18.84% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.84 $1.07 $4.41 $5.10
Number of Analysts 5 5 7 7
High Estimate $0.86 $1.10 $4.45 $5.38
Low Estimate $0.83 $1.03 $4.39 $4.77
Prior Year $0.72 $0.82 $3.32 $4.41
Growth Rate (Year over Year) 16.94% 30.49% 32.92% 15.67%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Feb 23, 2015 | 11:00 AM EST

Because now is not the time to get complacent in this market.

By

Doug Kass

 | Feb 23, 2015 | 8:51 AM EST
Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.
By

Jim Cramer

 | Feb 19, 2015 | 11:02 AM EST

Watch this leadership group that's been lagging.

By

Bret Jensen

 | Feb 17, 2015 | 8:00 AM EST

They're in the tech, pharma and biotechnology sectors.

bearishAbbvie rated new Sell at Citi

Feb 9, 2015 | 7:15 AM EST

ABBV was initiated with a Sell rating, Citigroup said. $48 price target. Humira biosimilars will likely create sizable competition. 

bearishAbbvie estimates, target reduced at BMO

Feb 4, 2015 | 8:11 AM EST

Shares of ABBV now seen reaching $62, according to BMO Capital. Estimates also cut, given higher hepatitis C discounts. Market Perform rating. 

bearishAbbvie estimates, target cut at Morgan Stanley

Feb 2, 2015 | 7:09 AM EST

ABBV estimates were reduced through 2016, Morgan Stanley said. Company is seeing lower hepatitis-C sales. Equal-weight rating and new $65 price target. 

By

Bret Jensen

 | Jan 29, 2015 | 9:46 AM EST

I am adding allocation to healthcare.

updateJP Morgan Healthcare Conf.

Jan 14, 2015 | 6:41 AM EST

JPMorgan Healthcare Conference (Day 3 of 4) - 01/12/15 - 01/15/15 San Francisco, CA

bearishAbbvie downgraded at BofA/Merrill

Jan 9, 2015 | 7:09 AM EST

ABBV was downgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $70 price target. 

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in....
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a c...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.